Study of the safety concernig autolougaus adipose tissue-derived stem cells for osteoarthritis of knee joint.

Study of the safety concernig autolougaus adipose tissue-derived stem cells for osteoarthritis of knee joint. (autolougaus adipose tissue-derived stem cells for osteoarthritis of knee joint.)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTb040190123

Enrollment

Registered

2020-03-03

Start date

2019-06-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

Administer Lipogems products into knee joint space of degenerative osteoarthritis under general anesthesia.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 30 to 85 years of age 2) grade II-IV (Kellgren-Lawrence) by X-ray 3) persistent symptoms for more than 6 months 4) failure of conservative management 5) possibility general anesthesia

Exclusion criteria

Exclusion criteria: 1)History of active neoplasm and active inflammatory disease 2) severe symptom by cerebral infarction and pulmonary infarction 3) rheumatoid arthritis and gout 4) pregnancy or lactation 5) thrombocytopenia 6) participation in other clinical studies 7) positive test result against HIV, HBV, HCV, syphilis or HTLV-1 8) severe DM, heart failure or renal failure.

Design outcomes

Primary

Measure	Time frame
Adverse events	—

Secondary

Measure	Time frame
improvement effect	—

Countries

Japan

Contacts

Public ContactNaomi Masuda

Kanazawa Medical University Hospital

n-taka@kanazawa-med.ac.jp+81-76-218-8200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026